不同口服抗凝剂对心房患者认知功能的影响:贝叶斯网络元分析
Wanling Ning1, Shiheng Wang2, Hanqing Tang3
1Hunan University of Chinese Medicine, Changsha, China.
Medicine
|April 26, 2024
概括
与其他口服抗凝剂相比,维生素K对抗剂 (VKA) 可能最能降低心房患者的认知衰退. 需要进一步的研究来证实这些发现用于AF治疗.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 心房动 (AF) 是一种常见的心律失常症,需要口服抗凝剂 (OAC).
- 现有证据表明OAC和AF患者的认知衰退之间存在联系,但需要进一步调查.
- 这项研究解决了对OAC对AF认知功能的影响的证据需求.
研究的目的:
- 调查不同口服抗凝剂对心房患者认知衰退的比较作用.
- 确定哪些OAC在缓解AF认知障碍方面最有效.
主要方法:
- 在主要数据库 (PubMed,科学网,Embase,Cochrane图书馆) 进行了系统的文献搜索,截至2023年7月3日.
- 纳入的研究使用Cochrane工具和纽卡斯尔-太华尺度评估了偏差风险.
- 贝叶斯网络元分析 (NMA) 用于比较各种OAC对认知功能的有效性.
主要成果:
- 分析了包括882,847名患者在内的10项研究,包括维生素K抗体 (VKAs),华法林,达比加特兰,埃多克萨班,里瓦罗克萨班,阿皮克萨班,阿司匹林和克洛皮多格雷尔.
- 在减少AF患者认知衰退风险方面,VKAs表现出优于华法林的优势 (OR = -1.19,P <.05).
- 降低认知障碍的可能性最高的前三种药物是VKA (87%),里瓦洛克萨班 (62.2%),达比加特兰 (60.8%).
结论:
- 维生素K抗剂 (VKA) 似乎是降低心房患者认知能力下降风险的最有效干预措施.
- 该研究强调需要高质量的,大规模的,多中心的随机对照试验来验证这些发现并提供强有力的证据.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
522
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
522
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
496
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
496


